COX-2/HDAC6-IN-1

COX-2/HDAC6-IN-1 (Compound 11e) 是一种双重 COX-2/HDAC6 抑制剂(HDAC6 IC50 = 0.12 μM,COX-2 IC50 = 0.66 μM),可增强 α-tubulin 乙酰化水平、调控表观遗传基因表达、抑制促炎介质(COX-2、IL-1β、IL-6 和 TNF-α)的表达、促进 Amyloid-β 清除、减少 Tau 蛋白过度磷酸化、通过稳定 MAP2 维持神经元形态、通过调节突触素保护突触完整性并恢复记忆相关基因的表达,具有神经保护活性,可在 Scopolamine (MS-P46812) 诱导的阿尔茨海默病小鼠模型中改善学习与记忆能力,可用于阿尔茨海默病的相关研究。
COX-2/HDAC6-IN-1
产品编号: MS-U37340 分子式: C23H25N3O7S 分子量: 487.53
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

COX-2/HDAC6-IN-1 (Compound 11e) 是一种双重 COX-2/HDAC6 抑制剂(HDAC6 IC50 = 0.12 μM,COX-2 IC50 = 0.66 μM),可增强 α-tubulin 乙酰化水平、调控表观遗传基因表达、抑制促炎介质(COX-2、IL-1β、IL-6 和 TNF-α)的表达、促进 Amyloid-β 清除、减少 Tau 蛋白过度磷酸化、通过稳定 MAP2 维持神经元形态、通过调节突触素保护突触完整性并恢复记忆相关基因的表达,具有神经保护活性,可在 Scopolamine (MS-P46812) 诱导的阿尔茨海默病小鼠模型中改善学习与记忆能力,可用于阿尔茨海默病的相关研究。

生物实验数据

生物活性 COX-2/HDAC6-IN-1 (Compound 11e) is a dual COX-2/HDAC6 inhibitor (HDAC6 IC50 = 0.12 μM, COX-2 IC50 = 0.66 μM) that enhances α-tubulin acetylation, regulates epigenetic gene expression, suppresses the expression of pro-inflammatory mediators (COX-2, IL-1β, IL-6, and TNF-α), promotes Amyloid-β clearance, reduces Tau hyperphosphorylation, maintains neuronal morphology by stabilizing MAP2, protects synaptic integrity by modulating synaptophysin, and restores the expression of memory-related genes; it exhibits neuroprotective activity, improves learning and memory in Scopolamine (MS-P46812)-induced Alzheimer's disease mouse models, and can be used for research related to Alzheimer's disease.
IC50 & Target

HDAC6

0.12 μM (IC50)

COX-2

0.66 μM (IC50)

IL-6

 

IL-1β

 

体外研究
(In Vitro)

COX-2/HDAC6-IN-1 可强效抑制 HDAC6 (IC50 = 0.12 μM) 和 COX-2 (IC50 = 0.66 μM)。

体内研究
(In Vivo)

COX-2/HDAC6-IN-1 (1 mg/kg/天;腹腔注射;14 天) 在 Scopolamine (MS-P46812) 诱导的阿尔茨海默病小鼠模型中改善学习和记忆能力。

Animal Model: albino mice (male, 8-10 weeks old, 30-35 g, scopolamine-induced AD model)
Dosage: 1 mg/kg/day
Administration: i.p.; 14 days
Result: Produced a 4.3-fold increase in spontaneous alternation percentage in the Y-maze test compared to the scopolamine-induced AD group, and a 2.2-fold and 3.6-fold increase compared to the compound 10a and 11a groups, respectively.
Reduced the time to reach the ground in the pole climbing test by 42.3% compared to the scopolamine-induced AD group, with times 27% and 11.4% lower than the compound 10a and 11a groups, respectively.
Decreased GFAP gene expression by 54.7% (to 1.019 ± 0.05 RCN) compared to the scopolamine-induced AD group.
Increased MAP2 gene expression by 46.5% (to 0.747 ± 0.03 RCN) compared to the scopolamine-induced AD group.
Increased synaptophysin gene expression by 39.2% (to 0.891 ± 0.08 RCN) compared to the scopolamine-induced AD group.
Reduced Aβ1-40 concentration to 19.71 ± 2.13 pg/mg protein (62.41% decrease) compared to the scopolamine-induced AD group.
Reduced IL-1β concentration to 1.8 ± 0.4 pg/mg protein (71.8% decrease) compared to the scopolamine-induced AD group.
Reduced IL-6 concentration to 6.96 ± 1.55 pg/mg protein (67.7% decrease) compared to the scopolamine-induced AD group.
Reduced TNF-α concentration to 59.55 ± 3.17 ng/mg protein (65.07% decrease) compared to the scopolamine-induced AD group.
Increased acetylated histone H3 protein expression by 2-fold (to 0.7 ± 0.04 pg/mg protein) compared to the scopolamine-induced AD group.
Increased acetylated α-tubulin protein expression by 3.03-fold (to 1 ± 0.048 pg/mg protein) compared to the scopolamine-induced AD group.
Reduced COX-2 protein expression by 33.5% (to 0.355 ± 0.02 pg/mg protein) compared to the scopolamine-induced AD group.
Reduced MDA levels by 75% (to 1.3 ± 0.08 nmol/mg protein) compared to the scopolamine-induced AD group.
Increased GSH levels by 2.05-fold (to 7 ± 0.31 nmol/mg protein) compared to the scopolamine-induced AD group.
Reduced NO concentration by 83.2% (to 1.98 ± 0.23 μmol/mg protein) compared to the scopolamine-induced AD group.
Restored semi-normal histoarchitecture of the cerebral cortex with minimal pyknotic nuclei and pericellular edema; increased pyramidal cell counts and reduced total histopathologic scoring compared to the scopolamine-induced AD group.
Reduced insoluble Aβ plaque staining to 0.346 ± 0.108 compared to the scopolamine-induced AD group.
Reduced phosphorylated Tau immunoreactivity to 0.277 ± 0.066 (nearly normal levels) compared to the scopolamine-induced AD group.
Reduced phosphorylated STAT3 (705) expression to mild levels compared to the scopolamine-induced AD group.

化学信息

分子量 487.53
分子式 C23H25N3O7S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础